We are live on ! Find out more
KCM

Knoll Capital Management Portfolio holdings

AUM $180M
1-Year Est. Return 66.11%
This Fund
S&P 500
This Quarter Est. Return
-23.53%
1 Year Est. Return
+66.11%
3 Year Est. Return
+268.55%
5 Year Est. Return
+741%
10 Year Est. Return
+10,877.35%
AUM
$236M
AUM Growth
-$74.6M
Cap. Flow
+$3.11M
Cap. Flow %
1.32%
Top 10 Hldgs %
98.25%
Holding
19
New
–
Increased
2
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
CRBP icon
Corbus Pharmaceuticals
CRBP
+$2.22M
2
TOVX icon
Theriva Biologics
TOVX
+$935K

Top Sells

Rank Stock Value
1
APTO
Aptose Biosciences, Inc.
APTO
+$37.8K
2
ZSAN
Zosano Pharma Corporation
ZSAN
+$11.2K

Sector Composition

Rank Sector Weight
1 Healthcare 20.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDVN
1
DELISTED
MEDIVATION, INC.
MDVN
$187M 79.35%
4,397,838
– –
AMPE
2
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$9.79M 4.16%
11,294
– –
TOVX icon
3
Theriva Biologics
TOVX
$10.2M
$8.48M 3.6%
427
+38
+10% +$935K
ARCT icon
4
Arcturus Therapeutics
ARCT
$157M
$6.74M 2.86%
159,331
– –
ABEO icon
5
Abeona Therapeutics
ABEO
$345M
$5.51M 2.34%
54,391
– –
CRBP icon
6
Corbus Pharmaceuticals
CRBP
$170M
$4.33M 1.84%
91,667
+33,334
+57% +$2.22M
LUMO
7
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$3.67M 1.56%
11,382
– –
ADXS
8
DELISTED
Advaxis Inc
ADXS
$2.81M 1.19%
18,333
– –
ENLV icon
9
Enlivex Ltd
ENLV
$70.7M
$1.72M 0.73%
564
– –
LSTA icon
10
Lisata Therapeutics
LSTA
$15.2M
$1.49M 0.63%
6,667
– –
ALDX icon
11
Aldeyra Therapeutics
ALDX
$91.7M
$792K 0.34%
135,800
– –
ADXSW
12
DELISTED
Advaxis Inc Warrants
ADXSW
$731K 0.31%
112,500
– –
KERX
13
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$704K 0.3%
200,000
– –
NBSE
14
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$566K 0.24%
513
– –
IOVA icon
15
Iovance Biotherapeutics
IOVA
$2.23B
$559K 0.24%
97,100
– –
GLMD icon
16
Galmed Pharmaceuticals
GLMD
$3.94M
$483K 0.21%
361
– –
EVOK
17
DELISTED
Evoke Pharma
EVOK
$162K 0.07%
387
– –
ZSAN
18
DELISTED
Zosano Pharma Corporation
ZSAN
$74K 0.03%
27
-2
-7% -$11.2K
APTO
19
DELISTED
Aptose Biosciences, Inc.
APTO
$51K 0.02%
27
-17
-39% -$37.8K

Similar funds

MGWA
Monument Group Wealth Advisors Concord, Massachusetts $180M AUM 19.81% 1-Year Est. Return
AW
Alchemi Wealth Essex, Connecticut $180M AUM
FBC
Fairfield, Bush & Co Darien, Connecticut $180M AUM 39.51% 1-Year Est. Return
AIC
Aurora Investment Counsel Atlanta, Georgia $180M AUM 0.3% 1-Year Est. Return
AG
Amiral Gestion Paris, France $180M AUM 9.43% 1-Year Est. Return
PCA
Prospect Capital Advisors Sausalito, California $180M AUM 60.99% 1-Year Est. Return
HIC
Hamrick Investment Counsel Seattle, Washington $180M AUM
FFA
Frazier Financial Advisors Columbus, Ohio $181M AUM 11.16% 1-Year Est. Return

Knoll Capital Management's Q3 2015 Portfolio in Review

As of Q3 2015, Knoll Capital Management held 19 positions worth $236M, down 24% from $310M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Trading was light in Q3 2015: portfolio turnover was 0%. Knoll Capital Management opened no new positions and made no exits, leaving the 19-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 18% a quarter earlier.

  • Knoll Capital Management added most to Corbus Pharmaceuticals in Q3 2015, an estimated $2.22M increase.
  • Knoll Capital Management's biggest Q3 2015 reduction was Aptose Biosciences, Inc., cutting an estimated $37.8K.
  • Knoll Capital Management's ten largest holdings make up 98% of its $236M portfolio in Q3 2015.
  • Knoll Capital Management opened 0 new positions and closed 0 in Q3 2015.
  • Knoll Capital Management's portfolio value fell 24% quarter-over-quarter to $236M.

Based on Knoll Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.